Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men

February 14, 2022 updated by: Asmaa Abdel-mageed Muhammed, Aswan University Hospital

Obesity is associated with low testosterone in men and with dyslipidemia. Adropin hormone is negatively correlated with body mass index and is associated with dyslipidemia.

correlation between adropin and testosterone will be evaluated.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Obesity, a worldwide epidemic is associated with multiple adverse health outcome as diabetes mellitus, hypertension and cardiovascular diseases caused mainly by dyslipidemia linked to obesity. Low testosterone levels in obese men were found associated with dyslipidemia.

Adropin is a new metabolic hormone that was first isolated in liver and brain tissues, It was observed that mice fed on a high-fat diet (HFD) had a rapid increase in adropin expression compared to control values. In human also, adropin levels were negatively correlated with body mass index (BMI) and were associated with dyslipidemia.

Adiponectin is a protein that is mainly produced by white adipose tissue and has an important role in lipid metabolism. Serum adiponectin concentrations were decreased in obese compared to normal weight men and significantly correlated with testosterone level.

Study Type

Observational

Enrollment (Actual)

82

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Aswan, Egypt, 81528
        • Aswan University hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

obese and normal weight men from 18 years to 50 years

Description

Inclusion Criteria:

Age from 18 years to 50 years. Clinically free except from obesity

Exclusion Criteria:

  • Diabetes mellitus Hypertension Heart failure Kidney disease Smoking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
obese men
Adult obese men (BMI ≥ 30 kg/m2)
Diagnostic test: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
blood samples will be collected after 10 hours fasting
Diagnostic test: Total testosterone
blood samples will be collected after 10 hours fasting
Diagnostic test: Adropin
blood samples will be collected after 10 hours fasting
Diagnostic test: Adiponectin
blood samples will be collected after 10 hours fasting
normal men
normal weight men (18.5 ≤ BMI < 25 kg/m2 )
Diagnostic test: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
blood samples will be collected after 10 hours fasting
Diagnostic test: Total testosterone
blood samples will be collected after 10 hours fasting
Diagnostic test: Adropin
blood samples will be collected after 10 hours fasting
Diagnostic test: Adiponectin
blood samples will be collected after 10 hours fasting

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
changes in lipid profile (TC, TG, LDL, HDL) levels
Time Frame: 6 months
expected higher TC, TG, LDl levels and lower HDL levels in obese men compared to normal
6 months
changes in total testosterone levels
Time Frame: 6 months
expected lower testosterone levels in obese men compared to normal men
6 months
changes in adropin level
Time Frame: 6 months
expected lower adropin levels in obese men compared to normal men
6 months
changed in adiponectin levels
Time Frame: 6 months
expected lower adiponectin level in obese men compared to normal men
6 months
correlation between adropin and testosterone
Time Frame: 6 months
6 months
correlation between adropin and adiponectin
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Aswan University Hospital

Investigators

  • Principal Investigator: Asmaa Abdelmageed Muhammed, Assistant lecturer, Aswan University hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2018

Primary Completion (Actual)

November 29, 2019

Study Completion (Actual)

January 7, 2020

Study Registration Dates

First Submitted

October 29, 2018

First Submitted That Met QC Criteria

October 29, 2018

First Posted (Actual)

October 30, 2018

Study Record Updates

Last Update Posted (Actual)

March 2, 2022

Last Update Submitted That Met QC Criteria

February 14, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Adropin in obese men

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe